Episode Details
Back to Episodes
XLV vs IBB Healthcare ETFs Compared | Business and Finance News
Description
When it comes to healthcare ETFs, XLV and IBB offer very different paths: XLV delivers steady, diversified growth with lower costs and less risk, while IBB targets high-growth biotech with higher volatility and fees. Over five years, XLV outperformed IBB with a $1,354 return vs. $1,167, plus a better dividend yield and smaller drawdowns — ideal for long-term stability. IBB’s aggressive bets on biotech could pay off big, but come with more risk. Choose XLV for consistency, or IBB for bold, high-reward plays.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/e8857b9bea12bedb